SPOTLIGHT: Novexel licenses anti-fungal drug

Novexel has agreed to license Indevus anti-fungal drug aminocandin for $1.5 million up front, $2.5 million on initiation of mid-level trials and up to $41 million in milestones and royalties. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.